Compounds being developed into drugs to treat atherosclerosis and obesity may put patients at risk for colorectal cancer, according to a report in the March issue of Nature Medicine.
Peroxisome proliferator-activated receptor-g (PPAR-g) is a transcription factor that activates genes involved in a number of important pathways in the body. Drugs that enhance the effects of PPAR-g are therefore being considered for use in treating certain diseases. But Raymond Dubois and colleagues found that activating PPAR-d increases the number and size of polyps--precancerous growths--in mice that are genetically predisposed to developing intestinal polyps.
Because larger polyps have a higher chance of progressing to a cancerous state, the authors caution that patients with pre-existing polyps may be at increased risk of developing colorectal cancer if they take drugs that enhance PPAR-g.
Raymond N. Dubois
Vanderbilt University Medical Center
Nashville, TN, USA,
Tel: +1 615 343 0527
Dr Dubois is in Colorado until 1 February, but available on his cellphone on +1 615 243 4747, or via Cynthia Manley (Vanderbilt Media Relations) on +1 615 838 0280
Also available online.
(C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking